Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil



ORAL OR INTRANASAL VACCINES USING HYDROPHOBIC COMPLEXES HAVING PROTEOSOMES AND LIPOPOLYSACCHARIDES

An immunogenic complex, essentially consisting of neisserial outer membrane protein proteosomes hydrophobically complexed to native purified bacterial lipopolysaccharide and formulated in accordance with the current invention for mucosal delivery such as via the oral or intranasal route is used as a vaccine. Specifically, a vaccine using shigella lipopolysaccharides complexed to proteosomes for such mucosal administration induces IgG and IgA antibodies in sera and in respiratory and intestinal fluids. Furthermore, such antibodies are associated with protection against shigella infection and these vaccines are herein demonstrated to protect against mucosal infection with shigella.


Docket:WRAIR 92-25

Publication/Issued No.:6,803,042

Publication/Issue Date:2004-10-12

Categories: Method,Vaccine

More Detail:Visit USPTO.GOVExternal link

Lab:WRAIR

Inventor(s):LOWELL, GEORGE


For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil
 

Last Modified Date: 25 Jul 2023

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRDC Public Affairs Office at:
USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil or by telephone at (301)619-2736.